Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 10, 2011 MAQUET Cardiovascular, a leading provider ... signed a three-year, dual-source contract with Premier Healthcare ... the Premier membership.  The contract includes the CS300 ... 50cc IABP Catheter, SENSATION® 7Fr. IABP Catheter and ...
... PRINCETON, N.J., Oct. 10, 2011 Pharmasset, Inc. (Nasdaq: ... two treatment arms to the ELECTRON trial of PSI-7977, ... chronic hepatitis C (HCV). The rapid and consistent antiviral ... to date provided the rationale for additional exploratory regimens ...
Cached Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 2MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 2Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 4
(Date:8/31/2014)... Franklin, TN (PRWEB) August 31, 2014 ... continuing education course provides an in-depth analysis ... and treatment of selected shoulder complex conditions. Over ... utilizing case studies, clinical reasoning and problem solving ... algorithm-based examination format for the special tests of ...
(Date:8/31/2014)... 31 August 2014: Drinking tea reduces non-cardiovascular mortality by ... at ESC Congress today by Professor Nicolas Danchin from ... choose between tea or coffee it,s probably better to ... our way of life. Their effects on cardiovascular (CV) ... divergent results. We investigated the effects of coffee and ...
(Date:8/30/2014)... 2014: A new batteryless cardiac pacemaker based on ... was presented at ESC Congress 2014 today by ... not require battery replacement. , Mr Zurbuchen, a ... ARTORG, University of Bern, Switzerland, said: "Batteries are ... they reach a critically low energy level, physicians ...
(Date:8/30/2014)... MN (PRWEB) August 31, 2014 As ... in home renovation, especially spa style bathrooms and in-home ... (NASS) has observed an increase in interest not only ... the history, culture and health benefits of sauna. ... Finnleo , the North American Sauna Society provides a ...
(Date:8/30/2014)... 2014 UWDress.com, a distinguished wedding dress supplier, ... first range of fashionable outfits. Recently, the company has unveiled ... As an autumn special offer, all these brand new products ... , “We are excited to unveil the new and ... high quality products are available at low prices now. The ...
Breaking Medicine News(10 mins):Health News:North American Seminars Master Clinicians Advanced Shoulder Course Receives PT Continuing Education Course Approval in Georgia, Pennsylvania, Massachusetts and Virginia 2Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture 2Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2
... See health and economic data like you,ve never ... statistics guru Hans Rosling will show how ... data. He will also illustrate how the convergence of ... countries into "Western" and "developing" categories an outdated concept.On ...
... Sports Medicine Provider Times Implementation to ... ALLENTOWN, Pa., May 21 Allscripts announced today that ... medicine in Pennsylvania,s Lehigh Valley, has selected the ... (EHR) and Practice Management (PM) ...
... , May 21 For the second year in ... fans to donate blood through the Red Cross by joining ... ) Red Cross Racing is a program designed to ... times they donate. Participants of this program can get points ...
... neuropathy than blood glucose levels, study suggests , , THURSDAY, ... levels of triglyceride fats are at increased risk of ... or damage of nerves that results in numbness, tingling ... researchers say. , A study by U.S. researchers ...
... A new study published online in Nature Immunology ... immunoglobulin (lg) alleles pair up in the nucleus at stages that ... and Igk) loci. Researchers led by Jane A. Skok ... of Medicine and a member of the NYU Cancer Institute, showed ...
... patient care with PDA-using nursing students in clinical ... illness, enlisting video games to improve analytical and ... myth-busting in advanced pain management courses are some ... at the first international Health Professions Education (HPE) ...
Cached Medicine News:Health News:Gapminder's Hans Rosling Brings Poverty, Health Data to Life at Wilson Center 2Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 2Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 3Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 4Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 5Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:High Blood Fats Tied to Diabetic Nerve Loss 2Health News:NYU School of Medicine pathology researchers solve another mystery in B lymphocyte development 2Health News:Health Professions Education Conference features 'Headspace Theater,' serious gaming, PDAs 2
... Rhe Vivid 7 system is GEs ... new level of image quality to echocardiography, ... diagnostic confidence to clinicians.,By listening to customer ... created the first ergonomically-designed cardiovascular system that ...
... the launch of the NCP-2, ACS proudly ... has given physicians more tools for assessing ... first and only complete ECP Treatment Report.,The ... software program that allows both physicians and ...
... Radi invented the guidewire-mounted pressure sensor ... PressureWire5 Sensor is the only sensor ... temperature and flow. With significantly improved ... as your primary guidewire, as well ...
... The revolutionary Powerheart AED G3-Automatic simplifies the rescue ... shock button. All that you have to do ... cardiac arrest. Once the defibrillation pads are attached ... heart rhythm, analyzes the rhythm using the patented ...
Medicine Products: